Praca z sesji tematycznych<br>Imiquimod for the treatment of actinic keratosis

Igor Michajłowski; Adam Włodarkiewicz; Michał Sobjanek; Waldemar Placek

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2009
vol. 96

Send email

Copy url:

abstract:

Praca z sesji tematycznych
Imiquimod for the treatment of actinic keratosis

Igor Michajłowski

,

Adam Włodarkiewicz

,

Michał Sobjanek

,

Waldemar Placek

Przegl Dermatol 2009; 96, 153–158

Online publish date: 2009/04/30

View full text Get citation

Imiquimod (IM) is an agonist of Toll-like receptors and stimulates an innate and acquired immune response by induction of synthesis and release of many cytokines. It shows indirect antiviral and antineoplastic action and causes cell destruction by means of apoptosis. Numerous studies have proved the efficacy of IM in the treatment of precancerous lesions and in situ cancers of skin and mucosa.
The article presents the current knowledge on the treatment of the most frequent precancerous condition, actinic keratosis, with the use of IM. Very good cosmetic effect seems to be a particular advantage of IM therapy. Treatment of the whole area of photodamaged skin (also subclinical lesions) determines better long-term therapeutic effect.

keywords:

Praca z sesji tematycznychImiquimod for the treatment of actinic keratosis

Igor Michajłowski , Adam Włodarkiewicz , Michał Sobjanek , Waldemar Placek

actinic keratosis, imiquimod, treatment

Praca z sesji tematycznych
Imiquimod for the treatment of actinic keratosis

Igor Michajłowski

,

Adam Włodarkiewicz

,

Michał Sobjanek

,

Waldemar Placek